Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to -$2.1 million.

  • Perspective Therapeutics' Net Cash Flow rose 9189.29% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.7 million, marking a year-over-year decrease of 19587.23%. This contributed to the annual value of $52.2 million for FY2024, which is 54372.61% up from last year.
  • According to the latest figures from Q3 2025, Perspective Therapeutics' Net Cash Flow is -$2.1 million, which was up 9189.29% from -$15.6 million recorded in Q2 2025.
  • In the past 5 years, Perspective Therapeutics' Net Cash Flow registered a high of $132.9 million during Q1 2024, and its lowest value of -$164.9 million during Q4 2024.
  • For the 5-year period, Perspective Therapeutics' Net Cash Flow averaged around $1.0 million, with its median value being -$6.3 million (2022).
  • In the last 5 years, Perspective Therapeutics' Net Cash Flow surged by 722980.65% in 2021 and then tumbled by 178522.58% in 2024.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Net Cash Flow stood at $37.9 million in 2021, then tumbled by 192.1% to -$34.9 million in 2022, then surged by 74.94% to -$8.7 million in 2023, then plummeted by 1785.23% to -$164.9 million in 2024, then surged by 98.73% to -$2.1 million in 2025.
  • Its Net Cash Flow stands at -$2.1 million for Q3 2025, versus -$15.6 million for Q2 2025 and -$17.2 million for Q1 2025.